Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.
- Splash Beverage initiates US veterinary development for CannEpil®
- Lupvindol Biosciences to lead FDA regulatory and pharmaceutical strategy
- Focus on canine oncology and chronic pain management
- Program navigates FDA Center for Veterinary Medicine approval pathways
- Argent retains CannEpil® IP and royalty participation across markets
US Veterinary Development Program Underway
Argent BioPharma Ltd (ASX:RGT) has reached a significant operational milestone with the commencement of a US veterinary pharmaceutical development program for CannEpil®, its cannabinoid epilepsy therapy. The program is being executed by Splash Beverage Group, Argent’s exclusive global licensing partner, in collaboration with Lupvindol Biosciences Ltd. This marks the first concrete step following Argent’s recent strategic expansion of CannEpil® into veterinary healthcare.
The initial development focus will be on companion-animal oncology and chronic pain management, with canine applications expected to lead. The program is structured to progress through the US Food and Drug Administration’s Center for Veterinary Medicine (FDA CVM), beginning with the Investigational New Animal Drug (INAD) process and aiming for Conditional Approval, establishing a clear regulatory pathway for CannEpil® in the animal health sector.
Experienced Leadership with Proven Track Record
Heading the veterinary program is Dr Hunter Land, CEO of Lupvindol Biosciences and a veteran of cannabinoid pharmaceutical development. Dr Land was the first full-time US R&D employee at GW Pharmaceuticals, contributing to the development of Epidiolex® and Sativex®, two pioneering FDA-approved cannabinoid medicines. His expertise, combined with Lupvindol’s broader team skilled in FDA regulatory strategy and clinical development, significantly strengthens the program’s execution capabilities.
This appointment underscores Argent’s commitment to leveraging top-tier scientific and regulatory talent to navigate the complex FDA veterinary approval process. It also signals confidence in CannEpil®’s potential to address unmet needs in veterinary oncology and pain management.
Strategic Value and Intellectual Property Retention
Despite licensing CannEpil® globally to Splash, Argent BioPharma retains full ownership of all existing and future intellectual property, manufacturing know-how, and regulatory assets related to the product. This arrangement ensures Argent’s ongoing participation in royalties from both human and veterinary markets, preserving long-term value for shareholders.
Chairman Roby Zomer highlighted the swift execution of the veterinary expansion strategy and expressed optimism about the collaboration with Lupvindol. He noted that while Argent maintains core assets, the licensing partner’s active development efforts are creating new commercial opportunities, enhancing the CannEpil® platform’s value beyond its original neurological indications.
The move into veterinary applications follows Argent’s recent licensing deal with Splash Beverage Group, which included US$5.5 million upfront via debt forgiveness and a 15% royalty structure on future global sales. These arrangements have bolstered Argent’s balance sheet and positioned CannEpil® for multi-market growth.
Implications for the Veterinary Cannabinoid Market
The launch of the US veterinary program places Argent BioPharma among a select group of companies pursuing cannabinoid therapies for animal health, a sector gaining traction amid rising interest in alternative treatments for chronic conditions in pets. The focus on oncology and chronic pain aligns with significant unmet clinical needs in companion animals, potentially opening a new revenue stream alongside Argent’s established human epilepsy market.
While specific timelines and financial projections remain undisclosed, the defined FDA regulatory pathway and experienced leadership team provide a foundation for measured progress. Observers should monitor forthcoming regulatory filings and clinical updates to gauge momentum and commercial potential.
Bottom Line?
Argent’s partnership-driven US veterinary push for CannEpil® could unlock new markets, but regulatory timelines and commercial returns remain to be seen.
Questions in the middle?
- How quickly will CannEpil® progress through the FDA veterinary approval stages?
- What commercial scale can the veterinary oncology and pain management markets provide?
- Will Argent pursue additional veterinary indications or expand beyond the US market?